LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Список акций・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Закрыт

СекторЗдравоохранение

56.54 -0.72

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

56.36

Макс.

57.32

Ключевые показатели
By Trading Economics
Доход	1.6B 2.7B
Продажи	-1B 11B
P/E Средняя по отрасли	16.073 49.8
Прибыль на акцию	1.58
Дивидендная доходность	4.29
Рентабельность продаж	23.309
Сотрудники	32,500
EBITDA	1.5B 3.7B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+12.04% upside

Дивиденды
By Dow Jones
Дивидендная доходность Средняя по отрасли	4.29% 2.25%
Следующий отчет о доходах	30 июл. 2026 г.
Дата следующей выплаты дивидендов	31 июл. 2026 г.
Следующая эксдивидендная дата	2 июл. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-817M 117B
Предыдущая цена открытия	57.26
Предыдущая цена закрытия	56.54

Новостные настроения

By Acuity

35%

65%

110 / 347 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

N/A / 50.57 Поддержка и Сопротивление

Bristol-Myers Squibb Co. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 апр. 2026 г., 11:14 UTC

Отчет

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

5 мая 2026 г., 18:12 UTC

Отчет

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 мая 2026 г., 13:54 UTC

Отчет

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 апр. 2026 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 апр. 2026 г., 14:13 UTC

Отчет

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 апр. 2026 г., 12:57 UTC

Отчет

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 апр. 2026 г., 11:19 UTC

Отчет

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 апр. 2026 г., 10:34 UTC

Отчет

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 апр. 2026 г., 21:23 UTC

Отчет

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

6 февр. 2026 г., 12:35 UTC

Отчет

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

5 февр. 2026 г., 15:25 UTC

Отчет

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

5 февр. 2026 г., 13:10 UTC

Отчет

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Bristol-Myers Squibb Co. Прогноз

Целевая цена

By TipRanks

12.04% рост

Прогноз на 12 месяцев

Средняя 64.29 USD 12.04%

Максимум 75 USD

Минимум 54 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Bristol-Myers Squibb Co. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

18 ratings

Покупка

Удержание

Продажа

Основано на мнении 18 аналитиков, присваивавших рейтинги акциям Bristol-Myers Squibb Co. – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

N/A / 50.57Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

All events are bearish.

Настроения

By Acuity

110 / 347Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.